Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
70 hedge funds and large institutions have $426M invested in Revance Therapeutics, Inc. in 2015 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 11 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 15
28% more capital invested
Capital invested by funds: $334M → $426M (+$92.8M)
1% more funds holding
Funds holding: 69 → 70 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less call options, than puts
Call options by funds: $427K | Put options by funds: $560K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$11.1M |
| 2 |
JP Morgan Chase
New York
|
+$8.68M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$3.46M |
| 4 |
Bank of New York Mellon
New York
|
+$2.43M |
| 5 |
VAM
Visium Asset Management
New York
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.83M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.28M |
| 3 |
JG
Jefferies Group
New York
|
-$1.69M |
| 4 |
ZDA
Zweig-DiMenna Associates
New York
|
-$1.41M |
| 5 |
Millennium Management
New York
|
-$1.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Citadel Advisors
Miami,
Florida
| – | -$846K | -49,974 | Closed |
|
|
CPH
77
C Partners Holding
Zurich,
Switzerland
| – | -$407K | -24,000 | Closed |
|
78
Arrowstreet Capital
Boston,
Massachusetts
| – | -$206K | -12,161 | Closed |
|
|
TC
79
TFS Capital
West Chester,
Pennsylvania
| – | -$190K | -11,213 | Closed |
|
|
BG
80
BlackRock Group
London,
United Kingdom
| – | -$11K | -626 | Closed |
|
|
MAA
81
Managed Account Advisors
Jersey City,
New Jersey
| – | -$4K | -258 | Closed |
|
RVNC Hedge Fund Activity: Q1 2015 in Review
70 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2015, worth a combined $426M — up 28% from $334M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RVNC positions and 11 closed out — a net gain of 1 holder — while 31 added to existing stakes and 15 trimmed.
The largest buyer was Franklin Resources, adding an estimated $11.1M. The largest seller was AllianceBernstein, cutting an estimated $9.83M.
- 70 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2015, up from 69 in Q4 2014.
- Funds reported $426M of Revance Therapeutics, Inc. stock for Q1 2015, up 28% quarter-over-quarter.
- 12 funds opened new Revance Therapeutics, Inc. positions in Q1 2015 and 11 closed out, a net change of +1 holder.
- The largest Revance Therapeutics, Inc. buyer in Q1 2015 was Franklin Resources, an estimated $11.1M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2015 was AllianceBernstein, an estimated $9.83M sold.
Based on aggregated 13F filings for Q1 2015.